Jäger Dirk, Filonenko Valeriy, Gout Ivan, Frosina Denise, Eastlake-Wade Susannah, Castelli Sandra, Varga Zsuzsanna, Moch Holger, Chen Yao-Tseng, Busam Klaus J, Seil Inka, Old Lloyd J, Nissan Aviram, Frei Claudia, Gure Ali O, Knuth Alexander, Jungbluth Achim A
Medizinische Onkologie NCT, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):77-83. doi: 10.1097/01.pai.0000213111.05108.a0.
NY-BR-1 was recently identified by autologous serological typing of the recombinant expression library in a breast cancer patient. Extensive reverse transcriptase-polymerase chain reaction analysis revealed the presence of NY-BR-1 in normal breast tissue and tumors derived thereof. Except normal testis, no other normal tissue or tumors showed NY-BR-1 expression. However, nothing is known about the expression of its actual antigen. In the present study, we describe the generation of 2 new monoclonal antibodies, NY-BR-1#2 and NY-BR-1#3, to NY-BR-1 for the analysis of its expression on a protein level employing recombinant NY-BR-1 protein for the immunization of BALB/c mice. In normal tissues, immunohistochemical testing demonstrates NY-BR-1 in a mostly focal fashion in the epithelia of ducts and acini of the mammary gland. No other tissue was immunopositive including testis. In tumors, homogenous staining can be seen in almost all ductal carcinomas in situ and/or the intraductal component of invasive carcinomas. Invasive carcinomas show a lower number of NY-BR-1-positive tumors. Initial higher numbers of NY-BR-1 mRNA-positive invasive carcinomas are most likely based on sample error owing to the contamination of tumor tissue with remnants of normal breast epithelium. Sweat gland carcinomas, which are related to breast cancer, are also positive in about one-third of the cases. These data indicate that NY-BR-1 is a differentiation antigen of the mammary gland that could be useful for diagnosis and/or immunotherapy of breast carcinomas.
NY-BR-1是最近在一名乳腺癌患者中通过重组表达文库的自体血清学分型鉴定出来的。广泛的逆转录酶-聚合酶链反应分析显示，NY-BR-1存在于正常乳腺组织及其衍生的肿瘤中。除正常睾丸外，没有其他正常组织或肿瘤显示NY-BR-1表达。然而，关于其实际抗原的表达情况却一无所知。在本研究中，我们描述了针对NY-BR-1产生的2种新的单克隆抗体NY-BR-1#2和NY-BR-1#3，使用重组NY-BR-1蛋白免疫BALB/c小鼠，以分析其在蛋白质水平上的表达。在正常组织中，免疫组织化学检测显示NY-BR-1主要以局灶性方式存在于乳腺导管和腺泡的上皮中。包括睾丸在内的其他组织均无免疫阳性。在肿瘤中，几乎所有原位导管癌和/或浸润性癌的导管内成分都可见均匀染色。浸润性癌中NY-BR-1阳性肿瘤的数量较少。最初较高数量的NY-BR-1 mRNA阳性浸润性癌很可能是由于肿瘤组织被正常乳腺上皮残余物污染导致的样本误差。与乳腺癌相关的汗腺癌在约三分之一的病例中也呈阳性。这些数据表明，NY-BR-1是一种乳腺分化抗原，可能对乳腺癌的诊断和/或免疫治疗有用。
